Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Presents New Data From Clinical Research for AGS-004 Patient-Specific Immunotherapy in Treatment of HIV
Argos Therapeutics Prices Initial Public Offering
Argos Therapeutics to Present Progress Update on ADAPT Phase 3 Trial with AGS-003 at 2014 Genitourinary Cancers Symposium